Biotech Values

[biomaven0]

pre-clinical data that may indicate that AP534 actually inhibits the oncogene from mutating at all?

The following article claims just that:

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
Source: Cancer cell [1535-6108] O'Hare yr:2009 vol:16 iss:5 pg:401 -412

They claim in preclinical models no single resistant mutation develops when you give 534. There are multiple mutations that can confer resistance, and this of course (if correct) argues why 543 should indeed be front line. But it's a long way from preclinical claims like this to becoming standard front-line in the real world, particularly with Gleevec going generic.

Peter